Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 137

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 137
---
 LLC Current Report on Form 8- K as Exhibit 1.1 December 2, 2022 2.1† Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011 Annual Report on Form 10-K as Exhibit 2.1 December 20, 2011 2.2† Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015 Quarterly Report on Form 10-Q, as Exhibit 2.1 May 11, 2015 3.1 Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company’s Form 8-K filed on April 6, 2016) Current Report on Form 8- K as Exhibit 3.3 April 6, 2016 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference from Exhibit 3.2 of the Company’s Form 10-Q filed on May 2, 2023) Quarterly Report on Form 10-Q, as Exhibit 3.2 May 2, 2023 3.3 Second Amended and Restated Bylaws (incorporated by reference from Exhibit 3.1 of the Company’s Form 8-K filed on January 30, 2023) Current Report on Form 8- K as Exhibit 3.2 January 30, 2023 4.1 Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc. Current Report on Form 8- K, as Exhibit 4.1 April 6, 2016 4.2 Form of Indenture Registration Statement on Form S-3, as Exhibit 4.2 December 2, 2019 4.3 Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate Current Report on Form 8- K, as Exhibit 4.1 March 23, 2017 4.4 Description of Registrant’s Securities Annual Report on Form 10-K, as Exhibit 4.4 November 25, 2019 4.5 Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and